ライフサイエンスコーパス: letrozole

1 1 mutations responded well to everolimus and letrozole.

2 h a clinical dose of the aromatase inhibitor letrozole.

3 gan but was not blocked by pretreatment with letrozole.

4 an in women, and brain uptake was blocked by letrozole.

5 s was increased, which could be inhibited by letrozole.

6 eroidal aromatase inhibitors anastrozole and letrozole.

7 pre-treatment with the aromatase inhibitor, letrozole.

8 ree survival compared with continuous use of letrozole.

9 ed a cell line model of resistance to the AI letrozole.

10 atively, the use of a more potent AI such as letrozole.

11 ns for memory deficits in women treated with letrozole.

12 sensitivity to the aromatase inhibitor (AI) letrozole.

13 ation of breast cancer cells to estrogen and letrozole.

14 reversed by withdrawal and reintroduction of letrozole.

15 poorest prognosis and may benefit most from letrozole.

16 AI therapy with anastrozole, exemestane, or letrozole.

17 , tumors eventually become insensitive to AI letrozole.

18 al E2 was 10.1% for anastrozole and 5.9% for letrozole.

19 onsidered for extended adjuvant therapy with letrozole.

20 rolonged the responsiveness of the tumors to letrozole.

21 sulfatase (STS) inhibitory pharmacophore to letrozole.

22 c administration of the aromatase inhibitor, letrozole.

23 s letrozole (2.5 mg per day) or placebo plus letrozole.

24 a embryo freezing with the concurrent use of letrozole.

25 after treatment with the aromatase inhibitor letrozole.

26 ars with node-positive disease, 65% received letrozole (122 of 188).

27 ly ATA 500 mg with TOR 60 mg (ATA + TOR), or letrozole 2.5 mg (LET).

28 se-free interval, to receive continuous oral letrozole 2.5 mg daily or continuous oral letrozole 2.5

29 al letrozole 2.5 mg daily or continuous oral letrozole 2.5 mg daily plus oral palbociclib 125 mg, giv

30 eoperative therapy consisting of 6 months of letrozole 2.5 mg orally daily plus lapatinib 1,500 mg or

31 re treated with the aromatase inhibitor (AI) letrozole (2.5 mg orally daily) and the anti-VEGF antibo

32 multicenter, open-label, phase III trial of letrozole (2.5 mg orally per day) with or without bevaci

33 y on a 3-weeks-on, 1-week-off schedule) plus letrozole (2.5 mg per day) or placebo plus letrozole.

34 d tamoxifen for >/= 1 year were treated with letrozole (2.5 mg) daily for >/= 2 years.

35 gned to receive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day fo

36 f anastrozole (1 mg) followed by 3 months of letrozole (2.5 mg), both given orally once daily, or 3 m

37 treatment groups of either continuous use of letrozole (2.5 mg/day orally for 5 years) or intermitten

38 y orally for 5 years) or intermittent use of letrozole (2.5 mg/day orally for 9 months followed by a

39 nadotropin (301 women), clomiphene (300), or letrozole (299).

40 e final analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368 [17.7%]).

41 t activity, the multiple gestation rate with letrozole (9 of 67 pregnancies, 13%) did not differ sign

42 ss in female mice that had been treated with letrozole, a potent aromatase inhibitor.

43 Administration of letrozole, a specific aromatase inhibitor, to these mice

44 sion of both estrogen types was greater with letrozole across the full range of BMIs in this study.

45 anada trial MA.17 demonstrated benefits with letrozole after 5 years of tamoxifen, oncologists needed

46 , 84 to palbociclib plus letrozole and 81 to letrozole alone.

47 ve in inhibiting growth of MCF-7Ca tumors as letrozole alone.

48 ENT plus letrozole also prevented lung colonization and growth of

49 nd treatment, indicating a similar effect of letrozole among all age groups.

50 ase activity required only one-fifth as much letrozole (an AI) in the presence of 25 nM LBH589 as in

51 ol and androgens on telomerase function, and letrozole, an aromatase inhibitor, blocked androgen effe

52 ments consisted of estradiol, an ER agonist; letrozole, an aromatase inhibitor; and fulvestrant, a pu

53 third generation aromatase inhibitors (AIs) letrozole, anastrozole, and the steroidal exemestane wer

54 classified as having a clinical response to letrozole and 15 being clinically resistant.

55 ssigned 165 patients, 84 to palbociclib plus letrozole and 81 to letrozole alone.

56 95% confidence interval [CI], 93 to 96) with letrozole and 91% (95% CI; 89 to 93) with placebo (hazar

57 all survival was 93% (95% CI, 92 to 95) with letrozole and 94% (95% CI, 92 to 95) with placebo (hazar

58 ence of contralateral breast cancer (67 with letrozole and 98 with placebo) and 200 deaths (100 in ea

59 aspects of low adherence (early cessation of letrozole and a compliance score of < 90%) were associat

60 Exploratory analysis showed similar DFS with letrozole and anastrozole in all evaluated subgroups.

61 On the basis of clinical response rates, letrozole and anastrozole were selected for further inve

62 Combination letrozole and bevacizumab was feasible with expected bev

63 The letrozole and buparlisib combination was safe, with reve

64 servation after ovarian stimulation with the letrozole and follicle-stimulating hormone protocol pres

65 Of those, 79 elected to undergo COS with letrozole and gonadotropins for embryo or oocyte cryopre

66 ion in 126 women with breast cancer by using letrozole and gonadotropins for the purpose of fertility

67 s equally well in the absence or presence of letrozole and had similar growth rates.

68 after treatment with the aromatase inhibitor letrozole and identified a D189Y mutation in the inhibit

69 baseline expression in tumors responsive to letrozole and increased expression with treatment in non

70 rated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and c

71 ione to physiologically ineffective doses of letrozole and oxidative stress byproducts produces AIMSS

72 No significant differences between letrozole and placebo were observed in scores on most su

73 The cell growth was inhibited by letrozole and stimulated by estradiol.

74 and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively.

75 ILC who responded to 3 months of neoadjuvant letrozole and were compared with a cohort of 14 respondi

76 erence in toxicity or QOL at 24 months among letrozole- and placebo-treated patients age >or= 70 year

77 The genes that change on letrozole are highly consistent between ILC and IDC.

78 Further longer-term studies with letrozole are needed in MAS.

79 cancer treated with the AIs anastrozole and letrozole are related to BMI.

80 Endocrine agents, such as letrozole, are established in the treatment of hormone-d

81 rse events were more common in the lapatinib-letrozole arm versus letrozole-placebo arm (diarrhea, 10

82 liferative effect of dihydrotestosterone and letrozole (aromatase inhibitor).

83 sease-free survival benefit was reported for letrozole as compared with tamoxifen, a protocol amendme

84 eceptor 2 (HER2), to the aromatase inhibitor letrozole as first-line treatment of hormone receptor (H

85 efficacy of palbociclib in combination with letrozole as first-line treatment of patients with advan

86 Letrozole, but not anastrozole, decreased bleeding episo

87 east cancer, resistance to continuous use of letrozole can be reversed by withdrawal and reintroducti

88 y potency on aromatase comparable to that of letrozole chosen as a reference compound.

89 treatment with gonadotropin, clomiphene, or letrozole, clinical pregnancies occurred in 35.5%, 28.3%

90 More women in the letrozole cohort had tumors larger than 2.0 cm (44.2% v

91 ole was significantly attenuated by DHA, and letrozole completely inhibited this suppressive action.

92 Novel ruthenium-letrozole complexes have been prepared, and cell viabili

93 d androstenedione levels cooperated with low letrozole concentrations and inflammatory mediators were

94 overcoming letrozole resistance in long-term letrozole cultured (LTLC) cells.

95 Letrozole derivatives were prepared bearing bis-sulfamat

96 Conclusion Letrozole did not demonstrate significantly superior eff

97 breast cancer, extended use of intermittent letrozole did not improve disease-free survival compared

98 Adding temsirolimus to letrozole did not improve PFS as first-line therapy in p

99 equential treatments involving tamoxifen and letrozole do not improve outcome compared with letrozole

100 ne of the aromatase inhibitors (anastrozole, letrozole, exemestane).

101 tly, breast cancer patients who responded to letrozole expressed significantly lower Cdc6 than those

102 Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluatio

103 with SE </=1.1%) for letrozole monotherapy, letrozole followed by tamoxifen, and tamoxifen followed

104 TLT-Ca cells were cultured in the absence of letrozole for 16 weeks.

105 ears, 1548 to tamoxifen for 5 years, 1540 to letrozole for 2 years followed by tamoxifen for 3 years,

106 randomly assigned to letrozole for 5 years, letrozole for 2 years followed by tamoxifen for 3 years,

107 nd 1548 to tamoxifen for 2 years followed by letrozole for 3 years.

108 years, or tamoxifen for 2 years followed by letrozole for 3 years.

109 of the trial, 1546 were randomly assigned to letrozole for 5 years, 1548 to tamoxifen for 5 years, 15

110 d patients enrolled and randomly assigned to letrozole for 5 years, letrozole for 2 years followed by

111 d patients randomly assigned to tamoxifen or letrozole for 5 years.

112 fen for 5 years and 2463 to monotherapy with letrozole for 5 years.

113 to assess the effect of the extended use of letrozole for an additional 5 years.

114 ve CDK4/6 inhibitor ribociclib combined with letrozole for first-line treatment in 668 postmenopausal

115 reduction in the hazard of a DFS event with letrozole for LB (hazard ratio [HR], 0.34; 95% CI, 0.21

116 Women receiving adjuvant letrozole for T1-3N0-3M0 breast cancer with a body mass

117 reduction in the hazard of a DFS event with letrozole for the LB subtype (HR, 0.65; 95% CI, 0.53 to

118 Ovarian stimulation with gonadotropins and letrozole for the purpose of fertility preservation is u

119 breast cancer and were receiving neoadjuvant letrozole for transcript profiling.

120 and that the combination of ovariectomy and letrozole further reduced the frequency of large lesions

121 red with 87.5% (86.0-88.8) in the continuous letrozole group (hazard ratio 1.08, 95% CI 0.93-1.26; p=

122 11.2-not estimable) for the palbociclib plus letrozole group (HR 0.299, 0.156-0.572; one-sided p<0.00

123 months (13.8-27.5) for the palbociclib plus letrozole group (HR 0.488, 95% CI 0.319-0.748; one-sided

124 months (13.1-27.5) for the palbociclib plus letrozole group (HR 0.508, 0.303-0.853; one-sided p=0.00

125 pregnancy loss (49 of 154 pregnancies in the letrozole group [31.8%] and 30 of 103 pregnancies in the

126 survival was 11.1 months (7.1-16.4) for the letrozole group and 18.1 months (13.1-27.5) for the palb

127 al was 10.2 months (95% CI 5.7-12.6) for the letrozole group and 20.2 months (13.8-27.5) for the palb

128 e survival was 5.7 months (2.6-10.5) for the letrozole group and 26.1 months (11.2-not estimable) for

129 [95% CI 27.9-36.0] for the palbociclib plus letrozole group and 27.9 months [25.5-31.1] for the letr

130 54 patients (24 [1%] in the intermittent letrozole group and 30 [1%] in the continuous letrozole

131 events had occurred in the palbociclib plus letrozole group and 59 in the letrozole group.

132 11 (13%) patients in the palbociclib plus letrozole group and two (2%) in the letrozole group disc

133 85.8% (95% CI 84.2-87.2) in the intermittent letrozole group compared with 87.5% (86.0-88.8) in the c

134 lib plus letrozole group and two (2%) in the letrozole group discontinued the study because of advers

135 (54%) of 83 patients in the palbociclib plus letrozole group versus one (1%) of 77 patients in the le

136 were four major congenital anomalies in the letrozole group versus one in the clomiphene group (P=0.

137 nsion (584 [24%] of 2417 in the intermittent letrozole group vs 517 [21%] of 2411 in the continuous l

138 3 [<1%] of 2417 patients in the intermittent letrozole group vs ten [<1%] of 2411 in the continuous l

139 e rate of contralateral breast cancer in the letrozole group was 0.21% (95% CI, 0.10 to 0.32), and th

140 ore than one patient in the palbociclib plus letrozole group were pulmonary embolism (three [4%] pati

141 group vs 517 [21%] of 2411 in the continuous letrozole group) and arthralgia (136 [6%] vs 151 [6%]).

142 etrozole group and 30 [1%] in the continuous letrozole group) had grade 3-5 CNS cerebrovascular ischa

143 le group and 27.9 months [25.5-31.1] for the letrozole group), 41 progression-free survival events ha

144 group vs ten [<1%] of 2411 in the continuous letrozole group).

145 group versus one (1%) of 77 patients in the letrozole group, leucopenia in 16 (19%) versus none, and

146 lbociclib plus letrozole group and 59 in the letrozole group.

147 ll multiple gestations in the clomiphene and letrozole groups were twins, whereas gonadotropin treatm

148 Women who received letrozole had more cumulative live births than those who

149 Ovarian stimulation with letrozole has been proposed to reduce multiple gestation

150 erapy in the form of the aromatase inhibitor letrozole has demonstrated activity in three clinical st

151 The addition of bevacizumab to letrozole improved PFS in hormone receptor-positive MBC,

152 rapamycin (mTOR) inhibitor temsirolimus with letrozole in AI-naive patients.

153 These results suggest greater benefit for letrozole in DFS, DDFS, and OS in patients with ER+/PgR+

154 as inhibited either by tamoxifen in vitro or letrozole in human subjects.

155 y test CDK4/6 inhibitors in combination with letrozole in independent two-arm trials.

156 Use of the antioestrogen letrozole in ovarian cancer has consistently demonstrate

157 ncer outcome compared with continuous use of letrozole in postmenopausal women.

158 rate the synergistic interaction of LBH589 + letrozole in suppressing the proliferation of hormone-re

159 The addition of palbociclib to letrozole in this phase 2 study significantly improved p

160 a (NCIC) MA.17 showing benefit from adjuvant letrozole in this setting necessitated termination of ac

161 R+/PgR+ tumors, implying greater activity of letrozole in tumors with a functional ER.

162 tment of BMS-754807 with either tamoxifen or letrozole in vivo elicited tumor regressions not achieve

163 institution phase II trial of everolimus and letrozole in women with recurrent EC.

164 of extended adjuvant endocrine therapy with letrozole, including intermittent administration, might

165 ate were similarly attenuated by infusion of letrozole into the median eminence of the hypothalamus.

166 their cytotoxicity to cancer cells, whereas letrozole is an aromatase inhibitor administered after s

167 studies, the combination of trastuzumab plus letrozole is equally effective in inhibiting growth of M

168 The magnitude of benefit of adjuvant letrozole is greater for patients diagnosed with lobular

169 Following letrozole, it was 1.56 pmol/L (range, 1.37 to 1.78 pmol/

170 + complete response) were observed (70% for letrozole-lapatinib and 63% for letrozole-placebo).

171 en receptor-positive/HER2-negative patients, letrozole-lapatinib and letrozole-placebo resulted in a

172 In the letrozole-lapatinib arm, the probability of achieving a

173 The combination of letrozole-lapatinib in early breast cancer was feasible,

174 tion between PIK3CA mutation and response to letrozole-lapatinib in HR-positive/HER2-negative early b

175 ene (TOR; complete estrogen blockade) versus letrozole (LET) in receptor-positive advanced breast can

176 s Group MA.17 trial examined the efficacy of letrozole (LET) started within 3 months of 5 years of ad

177 ur-arm option to 5 years of tamoxifen (Tam), letrozole (Let), or the agents in sequence (Let-Tam, Tam

178 yndrome, but aromatase inhibitors, including letrozole, might result in better pregnancy outcomes.

179 ndocrine therapy, the majority came from the letrozole monotherapy arm (n = 318), followed by sequent

180 5-year tamoxifen monotherapy arm or a 5-year letrozole monotherapy arm.

181 c breast cancer might be good candidates for letrozole monotherapy in the first-line setting regardle

182 Comparison of sequential treatments to letrozole monotherapy included patients enrolled and ran

183 8.7 years from randomisation (range 0-12.4), letrozole monotherapy was significantly better than tamo

184 ncer recurrence and mortality is obtained by letrozole monotherapy when compared with tamoxifen month

185 trozole do not improve outcome compared with letrozole monotherapy, but might be useful strategies wh

186 o-treat estimates (each with SE </=1.1%) for letrozole monotherapy, letrozole followed by tamoxifen,

187 cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 ye

188 the comparison of the sequential groups with letrozole monotherapy, there were no statistically signi

189 (n = 318), followed by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and

190 nts were randomly assigned to receive either letrozole (n = 2,061) or anastrozole (n = 2,075).

191 (5a reductase inhibitor; AvodartTM); (d) T + Letrozole (nonsteroidal aromatase inhibitor; FemeraTM);

192 e used to account for selective crossover to letrozole of patients (n=619) in the tamoxifen arm.

193 tocol amendment facilitated the crossover to letrozole of patients who were still receiving tamoxifen

194 tudy, we therefore focused on the effects of letrozole on long-term potentiation (LTP), which is an e

195 icities, and quality of life (QOL) impact of letrozole on older women.

196 atistically significant differences favoring letrozole only in patients age younger than 60 years (ha

197 that synergized strongly in combination with letrozole or 4-hydroxytamoxifen and fulvestrant.

198 Previous therapy included letrozole or anastrozole (100%), tamoxifen (48%), fulves

199 signed 750 women, in a 1:1 ratio, to receive letrozole or clomiphene for up to five treatment cycles,

200 leted 5 years of tamoxifen to receive either letrozole or placebo.

201 opausal women after 5 years of tamoxifen, to letrozole or placebo.

202 tor BMS-754807 alone and in combination with letrozole or tamoxifen.

203 d to receive first-line hormone therapy with letrozole or tamoxifen.

204 s trastuzumab provided superior benefit over letrozole or trastuzumab alone.

205 ue remaining after either endocrine therapy (letrozole) or chemotherapy (docetaxel), consistent with

206 ng 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June

207 There was no evidence that the benefit of letrozole over tamoxifen differed according to patients'

208 Breast International Group), the benefits of letrozole over tamoxifen were the same in ER+ tumors irr

209 evels were 4.6% for anastrozole and 2.0% for letrozole (P = .001).

210 reduced the serotonin/prolactin response and Letrozole partially blocked the effect of T.

211 ER+/PgR+ letrozole patients experienced significant benefit in di

212 antly greater for lapatinib-letrozole versus letrozole-placebo (48% v 29%, respectively; odds ratio [

213 duced the risk of disease progression versus letrozole-placebo (hazard ratio [HR] = 0.71; 95% CI, 0.5

214 common in the lapatinib-letrozole arm versus letrozole-placebo arm (diarrhea, 10% v 1%; rash, 1% v 0%

215 2-negative patients, letrozole-lapatinib and letrozole-placebo resulted in a similar overall clinical

216 ved (70% for letrozole-lapatinib and 63% for letrozole-placebo).

217 feasibility study to evaluate the safety of letrozole plus bevacizumab in patients with hormone rece

218 .6 months with letrozole to 20.2 months with letrozole plus bevacizumab.

219 onths with letrozole versus 47.2 months with letrozole plus bevacizumab.

220 valuate the clinical and biologic effects of letrozole plus lapatinib or placebo as neoadjuvant thera

221 creased Her-2 expression, the combination of letrozole plus trastuzumab provided superior benefit ove

222 Women with ER-positive tumors also received letrozole (plus a luteinizing hormone-releasing hormone

223 ong 838 eligible women, 305 (36%) received a letrozole prescription before April 2006.

224 omen who did or did not receive a subsequent letrozole prescription were described.

225 A significant increase in letrozole prescriptions was observed after the letter ma

226 AIs, but although this was significant with letrozole (r = 0.35; P = .013, and r = 0.30; P = .035 fo

227 ystemic administration of the AROM inhibitor letrozole reduced spine synapse density in the BL of adu

228 A P450arom inhibitor, letrozole, reduced 17beta-estradiol levels and completel

229 Letrozole reduces plasma E2 and E1S levels to a signific

230 ne dramatically lowered the concentration of letrozole required to engage TRPA1.

231 olism blocking agent, VN/14-1, in overcoming letrozole resistance in long-term letrozole cultured (LT

232 ate that discontinuing treatment can reverse letrozole resistance.

233 tinuing letrozole treatment on the growth of letrozole-resistant cells and tumors.

234 Letrozole response by clinical measurement (71% HER2 FIS

235 hat ENT treatment can be used to restore the letrozole responsiveness of ER-negative tumors.

236 lained infertility, ovarian stimulation with letrozole resulted in a significantly lower frequency of

237 Everolimus plus letrozole results in a high CBR and RR in patients with

238 his phase Ib study evaluated buparlisib plus letrozole's safety, tolerability, and preliminary activi

239 In addition, letrozole sex-specifically altered synaptic properties i

240 At 30 months median follow-up, letrozole significantly improved disease-free survival (

241 cultures from immature rats, treatment with letrozole significantly reduced spine synapses in the BL

242 patients (n = 219), addition of lapatinib to letrozole significantly reduced the risk of disease prog

243 xokinase-2 (HK2) in combination with the AI, letrozole, synergistically reduced cell viability in AI-

244 sistance to AIs, MCF-7aro cells resistant to letrozole (T+LET R), anastrozole (T+ANA R), and exemesta

245 by sequential tamoxifen-letrozole (n = 189), letrozole-tamoxifen (n = 176), and tamoxifen monotherapy

246 Those on letrozole/temsirolimus experienced more grade 3 to 4 eve

247 ratory analysis showed improved PFS favoring letrozole/temsirolimus in patients </= age 65 years (9.0

248 longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letroz

249 red more frequently among patients receiving letrozole than among those receiving placebo, including

250 tment with ENT alone and in combination with letrozole than in control tumors (P > 0.001).

251 he cumulative ovulation rate was higher with letrozole than with clomiphene (834 of 1352 treatment cy

252 les and were not sex-specifically altered by letrozole, the findings suggest sex-specific mechanisms

253 Two years of letrozole therapy did not increase predicted adult heigh

254 The addition of zoledronic acid to adjuvant letrozole therapy may protect against bone loss.

255 ritish Columbia (BC), letters about extended letrozole therapy were sent to eligible BC women, their

256 While receiving adjuvant letrozole therapy, she reported 3 months of worsening ba

257 ongation in median PFS from 15.6 months with letrozole to 20.2 months with letrozole plus bevacizumab

258 Letrozole-treated boys with idiopathic short stature (IS

259 In acute slices of letrozole-treated female mice with reduced estradiol ser

260 The cells isolated from these long-term letrozole-treated tumors (LTLT-Ca) were found to have de

261 In cells isolated from these long-term letrozole-treated tumors (LTLT-Ca), estrogen receptor-al

262 dy, we evaluated the effect of discontinuing letrozole treatment on the growth of letrozole-resistant

263 ly, in MCF-7Ca xenografts, a 6-week break in letrozole treatment prolonged the responsiveness of the

264 During letrozole treatment, a decrease in BPE occurred in 46% (

265 rs eventually begin to grow during continued letrozole treatment.

266 sion was observed with this second course of letrozole treatment.

267 pulation that compared extended intermittent letrozole use (n=2425) with continuous letrozole use (n=

268 ttent letrozole use (n=2425) with continuous letrozole use (n=2426).

269 median overall survival of 43.9 months with letrozole versus 47.2 months with letrozole plus bevaciz

270 The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm (hazard ratio

271 stimated overall survival rate was 89.9% for letrozole versus 89.2% for anastrozole arm (hazard ratio

272 compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients

273 verse events (> 5% of patients) reported for letrozole versus anastrozole were arthralgia (3.9% v 3.3

274 ths) was significantly greater for lapatinib-letrozole versus letrozole-placebo (48% v 29%, respectiv

275 The DFS hazard ratio (HR) for letrozole versus placebo in ER+/PgR+ tumors (N = 3,809)

276 ad an E2 value >or= 3 pmol/L after receiving letrozole, versus 20 of 54 (37%) patients after receivin

277 venile (prepubertal) female rats, wash-in of letrozole virtually abolished long-term potentiation (LT

278 fter treatment was discontinued for 6 weeks, letrozole was administered again.

279 s was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily.

280 Treatment with 6-12 months of anastrozole or letrozole was associated with decreases in BPE, which oc

281 with a higher incidence of hot flushes, and letrozole was associated with higher incidences of fatig

282 As compared with clomiphene, letrozole was associated with higher live-birth and ovul

283 The molecular response to letrozole was characterized and a four-gene classifier o

284 population-based setting, extended adjuvant letrozole was more common among younger women with highe

285 ant trend toward prolonged PFS for lapatinib-letrozole was seen in patients who experienced relapse l

286 Letrozole was superior to tamoxifen in both the normal s

287 was 10.9 QALMs compared with strategy B when letrozole was used as systemic therapy, whereas it was o

288 was 10.9 QALMs compared with strategy B when letrozole was used as systemic therapy, whereas it was o

289 owed by tamoxifen, and tamoxifen followed by letrozole were 78.6%, 77.8%, 77.3% for disease-free surv

290 he changes in gene expression in response to letrozole were highly similar between responding ILC and

291 Patients receiving adjuvant letrozole were randomly assigned to receive either upfro

292 nd 18.7%, respectively; pregnancy rates with letrozole were significantly lower than the rates with s

293 The sequence of effects in response to letrozole were similar in ovariectomized female and male

294 ase inhibitor (IC 50 = 0.6 nM, comparable to letrozole), whereas the ( S)-sulfamate, ( 40b) inhibited

295 ced or metastatic disease were randomized to letrozole with or without lapatinib, an epidermal growth

296 ian stimulation (COS) using a combination of letrozole with standard fertility medications on disease

297 up) 1-98 randomized clinical trial comparing letrozole with tamoxifen as adjuvant therapy for postmen

298 zole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the

299 ved adjuvant radiation therapy and initiated letrozole, with excellent compliance during the interval

300 d that extended intermittent use of adjuvant letrozole would improve breast cancer outcome compared w

301 a levels of leuprolide, interferon alpha-2b, letrozole, Y-27632, octreotide, and human growth hormone